1
|
Ramadan A, Mohammed A, Elnour AA, Sadeq A, Al Mazrouei N, Alkaabi M, Al-Kubaisi KA, Beshir SA, Menon V, AlAmoodi A, Sam KG, Saeed AAAM, Abdalla SF, Hussein SM. The flavonoid luteolin reduces mutant huntingtin aggregation and cytotoxicity in huntingtin-mutated neuroblastoma cells. Saudi Pharm J 2023; 31:101871. [PMID: 38125952 PMCID: PMC10731386 DOI: 10.1016/j.jsps.2023.101871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Accepted: 11/12/2023] [Indexed: 12/23/2023] Open
Abstract
Background Huntington's disease is an inherited progressive neurodegenerative disorder caused by an expansion of the polyglutamine tract leading to malformation and aggregation of the mutant huntingtin protein in the cell cytoplasm and nucleus of affected brain regions. The development of neuroprotective agents from plants has received considerable research attention. Objective Our study aims to investigate the neuroprotective effects of luteolin and the mechanisms that underline its potential mediated protection in the mutant htt neuroblastoma cells. Methods The mutant htt neuroblastoma cells were transfected with 160Q, and the control wild-type neuroblastoma cells were transfected with 20Q htt for 24 h and later treated with luteolin. Cell viability was determined by MTT and PI staining in both groups, while western blotting was used to evaluate caspase 3 protein expression. Aggregation formation was assessed via immunofluorescence microscopy. Also, western blotting was utilized to measure the protein expression of mutant htt aggregated and soluble protein, Nrf2 and HO-1. The impact of Nrf2 on luteolin-treated neuroblastoma cells was assessed using small interfering RNAs. Results Our study reports that luteolin can protect cultured cells from mutant huntingtin cytotoxicity, evidenced by increased viability and decreased apoptosis. Also, luteolin reduced the accumulation of soluble and insoluble mutant huntingtin aggregates in mutant htt neuroblastoma cells transfected with 160Q compared to the control wild-type. The mutant htt aggregate reduction mediated by luteolin appeared to be independent of the Nrf2 -HO-1 antioxidant pathway. Conclusion Luteolin presents a new potential therapeutic and protective agent for the treatment and decreasing the cytotoxicity in neurodegenerative diseases such as Huntington's disease.
Collapse
Affiliation(s)
- Azza Ramadan
- College of Pharmacy, Al Ain University, Abu Dhabi Campus Abu Dhabi, UAE, AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates
| | - Abuelnor Mohammed
- Department of Basic Medical Sciences, College of Medical, Dar Al Uloom University, Riyadh, Saudi Arabia
- Department of Histology and Embryology, School of Basic Medical Sciences, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, People’s Republic of China
| | - Asim Ahmed Elnour
- Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Abu Dhabi campus, Abu Dhabi-United Arab Emirates (UAE), AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates
| | - Adel Sadeq
- Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates
| | - Nadia Al Mazrouei
- Department of Pharmacy Practice and Pharmacotherapeutics, Faculty of Pharmacy, University of Sharjah, United Arab Emirates
| | - Maisoun Alkaabi
- New Medical Center (NMC) Royal Women’s Hospital, Abu Dhabi, United Arab Emirates
| | - Khalid Awad Al-Kubaisi
- Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy-University of Sharjah, United Arab Emirates
| | - Semira Abdi Beshir
- Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College For Girls, Dubai, United Arab Emirates
| | - Vineetha Menon
- Department of Pharmacy Practice, College of Pharmacy, Gulf Medical University, United Arab Emirates
| | - Abdulla AlAmoodi
- Ambulatory Healthcare Services, Academic Affairs, Abu Dhabi Health Services (SEHA), United Arab Emirates
| | - Kishore Ganana Sam
- Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai, United Arab Emirates
| | - Ali Awadallah Ali Mohamed Saeed
- Department of Pharmacology, Faculty of Clinical and Industrial Pharmacy, National University-Sudan, Mycetoma Research Center, Khartoum, Sudan
| | - Sami Fatehi Abdalla
- Clinical Department, College of Medicine, University of Almaarefa, Riyadh, Saudi Arabia
| | - Samah Mohammed Hussein
- Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia
| |
Collapse
|